Skip to main content

Table 3 Doppler echocardiography parameters in the study patients

From: Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial

Parameters

Mean ± SD

P-value

 

Group 1 (n = 20)

Group 2 (n = 20)

Group 3 (n = 20)

Groups 1 & 2

Groups 2 & 3

Groups 1 & 3

ANOVA

EM

101.0 ± 29.34

108.3 ± 14.07

100.2 ± 10.51

0.433

0.105

0.926

0.543

AM

74.37 ± 24.04

83.5 ± 24.2

71.84 ± 20.73

0.334

0.196

0.764

0.410

ET

79.94 ± 17.49

75.49 ± 26.75

70.75 ± 10.14

0.607

0.544

0.098

0.430

AT

58.01 ± 12.93

49.07 ± 19.73

57.81 ± 16.64

0.168

0.232

0.971

0.302

PAT

121.4 ± 17.99

117.8 ± 38.88

120.2 ± 20.56

0.758

0.847

0.873

0.942

E/AM

1.41 ± 0.51

1.39 ± 0.42

1.50 ± 0.45

0.899

0.535

0.639

0.818

  1. Group 1: control group; group 2: intervention with deferoxamine 10-times the doxorubicin dose; group 3: intervention with deferoxamine 50 mg/kg
  2. EM early diastolic velocity of mitral valve, AM late diastolic velocity of mitral valve, ET early diastolic velocity of tricuspid valve, AT late diastolic velocity of tricuspid valve, PAT Pulmonary acceleration time, E/AM early-to-late diastolic velocity of mitral valve